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Abstract 
Background.  The QuantiFERON®-TB Gold assay is a new test for latent tuberculosis infection. 
It is thought to be more reliable and have fewer false positives than the tuberculin skin test 
(TST).  Both tests are dependent on a normal immune system for diagnostic accuracy.  However, 
no comparisons of the two tests have assessed the accuracy in pregnant women. This 
investigation assessed the consistency of results between the two tests in both pregnant and non-
pregnant women.  
Methods.  The study included 152 women presenting for care at the Sedgwick County Health 
Department. They were divided into two groups of pregnant and non-pregnant women.  Both 
groups were assessed with the Quantiferon assay and the TST.  Subjects were adults between the 
ages of 18 and 45.  All had a pregnancy test and a negative HIV test.   None had existing 
morbidities that would influence the test results. 
Results.  Concordant results between the tests were shown in 131 subjects (86.2%).  Of the 
pregnant women, 91.2% had concordant results.  Of the non-pregnant women, 76% had 
concordant results.  Significantly more discordant results occurred in non-pregnant women 
(p<.022). 
Conclusion.  Current guidelines favor using either test in healthy individuals.  Although more 
discordant results occurred in the non-pregnant women, both tests were effective in pregnant 
women.  Thus, TST and Quantiferon are accurate to use in pregnant women.  The decision to use 
either test in pregnant women should be based mainly on the compliance of the patient to return 
to have the TST read.  KJM 2010; 3(2):24-30. 
 
 
Introduction 
Tuberculosis is a communicable disease 
caused by infection with M. tuberculosis 
complex organisms, which typically spreads 
to new hosts via airborne droplet nuclei 
from patients with respiratory tuberculosis 
disease.1 A newly-infected individual can 
become ill from tuberculosis within weeks 
to months, but most infected individuals 
remain well.  Latent tuberculosis infection 
(LTBI),  a non-communicable asymptomatic 
 
condition, persists in some who might 
develop tuberculosis disease months or 
years later.1,2   
Until recently, the tuberculin skin test 
(TST) was the only available method for 
diagnosing LTBI.  Cutaneous sensitivity to 
tuberculin develops from 2 to 10 weeks after 
infection.   This test uses a small amount of 
purified protein derivative (PPD) prepared 
from M. tuberculosis, placed intradermally 
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and measured 48 to 72 hours later to identify 
the delayed hypersensitivity response, 
indicating previous infection.2 However, 
some infected individuals, including those 
with a wide range of conditions hindering 
immune functions, but also others without 
these conditions, do not respond to 
tuberculin. Conversely, some individuals 
who are unlikely to have M. tuberculosis 
infection exhibit sensitivity to tuberculin and 
have positive tuberculin skin test (TST) 
results after vaccination with bacilli 
Calmette-Guerin (BCG) infection with 
mycobacteria other than M. tuberculosis 
complex or undetermined other factors.3-5   
LTBI must be distinguished from 
tuberculosis disease, a reportable condition 
which usually involves the lungs and lower 
respiratory tract, although other organ 
systems also may be affected.  Tuberculosis 
disease is diagnosed from historical, 
physical, radiological, histological, and 
mycobacteriological findings.1,5,6 
The QuantiFERON®-TB Gold test is a 
new test for cell mediated immune (CMI) 
responses to peptide antigens that simulate 
mycobacterial proteins.4  These proteins, 
ESAT-6 and CFP-10, are absent from all 
BCG strains and from most non-tuberculosis 
mycobacteria with the exception of M. 
kansasii, M. szulgai, and M. marinum.  It is 
thought to be more reliable and has fewer 
false positives than the TST.  Individuals 
infected with M. tuberculosis complex 
organisms usually have lymphocytes in their 
blood that recognize these and other 
mycobacterial antigens.  This recognition 
process involves the generation and 
secretion of the cytokine, IFN-γ.  The 
detection and subsequent quantification of 
IFN-γ forms the basis of this test.4,7-9   
Since the Quantiferon test is dependant 
on immune mediators and factors, like TST, 
it also is affected by changes in the immune 
system of the tested subjects.10,11  Both tests 
are dependent on a normal immune system 
for diagnostic accuracy.  Therefore, any 
condition that alters the immune system, 
especially that will depress this system, 
theoretically can cause false-negative results 
with this test.12-16 
In the US Centers for Disease Control 
and Protection (CDC) guidelines of 2003, 
pregnancy was one of the conditions in 
which use of this test was not recommended, 
because pregnancy has the potential to 
decrease the immune response.7  In the CDC 
guidelines of 2005, the spectrum to use 
QuantiFERON®-TB Gold was broadened 
and pregnancy no longer showed as one of 
the conditions for which it is not 
recommended.17 However, no serious 
investigations have been done concerning 
the correlation of pregnancy with the 
accuracy of the Quantiferon assay, and the 
CDC arbitrarily included, then excluded,  
pregnancy in the contraindication category 
for that assay. 
This investigation assessed the 
consistency of results between the the 
QuantiFERON®-TB Gold assay and the TST 
in both pregnant and non-pregnant women. 
 
Methods 
Study population.  Subjects were women 
presenting for care at the Sedgwick County 
Health Department.  Eligibility criteria 
included: 
•
 Female patients  
•
 Age between 18 and 45 years old 
•
 HIV negative status 
•
 No history of corticosteroids use, 
taking the equivalent of greater than 15 
mg/day of prednisone for one month or 
more 
•
 Non-diabetic patients 
•
 Non-transplant patients 
•
 No current treatment with immuno-
suppressive drugs 
•
 No renal failure 
Kansas Journal of Medicine 2010                                   QuantiFERON-TB Gold Assay 
26 
 
•
 No pre-existing hematologic problems 
(e.g., myeloproliferative disorders, 
leukemias, and lymphomas) 
•
 No pre-existing malignancies (e.g., 
carcinoma of the head, neck, or lung) 
Exclusion criteria included: 
•
 Abortion prior to study completion  
•
 Conversion to HIV positive during 
study participation  
•
 Any diversion from the eligibility 
criteria 
•
 Withdrawal of informed consent by the 
subject 
Procedures. Approval of the Institutional 
Review Board at the University of Kansas 
School of Medicine-Wichita was obtained.  
Subjects were recruited by clinical personnel 
at the Sedgwick County Health Department.  
All pregnant subjects were recruited during 
visits to the prenatal clinic.  Non-pregnant 
subjects were recruited from other Health 
Department clinics. 
Each woman signed an informed consent 
in either Spanish or English, as appropriate.  
Each subject was given four clinical tests.  
Two tests determined eligibility for 
participation:  a pregnancy test and an HIV 
test.  Then, the two TB tests (Quantiferon 
and TST) were given when eligibility was 
established.  Women who were pregnant 
received the TST as part of their usual care 
regardless of study participation. 
Blood was drawn by clinical personnel 
at the Health Department to determine 
pregnancy (for the non-pregnant control 
group) and HIV status.  Pregnant subjects 
did not receive an additional pregnancy test 
because they entered the study with a known 
pregnancy status from the prenatal clinic.  
Subjects were required to return to the 
Health Department two to three days after 
the TST to have the test results read by a 
trained person. Laboratory testing was 
performed according to standard Health 
Department policy and procedures.   
Tuberculin Skin Testing.  The TST was 
administered by the Mantoux method using 
0.1 ml (5TU) of Tubersol (Connaught 
Laboratories Inc., Toronto, Ontario) and 
interpreted by trained clinical personnel 
according to American Thoracic Society 
(ATS)/CDC guidelines.18 Transverse indur-
ation at the TST site was measured 48 to 78 
hours after injection of purified protein 
derivative (PPD). TST results were inter-
preted using the risk-stratified interpretation 
of induration as recommended by the 
ATS/CDC guidelines. 
QuantiFERON®-TB Gold Assay.  The 
assay was performed and interpreted 
according to the manufacturer’s instructions 
using previously described cut-points to 
identify infected persons.  
Statistical measures. Statistical measures 
of agreement (kappa) were performed using 
MedCalc for Windows, version 10.1.3 
(MedCalc Software, Mariakerke, Belgium). 
All other tests were conducted in StatXact, 
version 8.0.0, Cytel Studio. 
 
Results 
A total of 152 women (102 pregnant 
subjects and 50 non-pregnant controls) 
participated in the study.  All met study 
criteria to participate.  Group demographics 
according to pregnancy status are shown in 
Table 1.  Pregnant subjects were younger, 
with greater representation of Caucasians 
and Hispanics.  Non-pregnant subjects were 
older and more racially diverse, but with 
fewer Hispanics. 
Table 2 shows concordant results 
between the two TB tests in 131 subjects 
(86.2%).  A kappa statistic revealed fair 
agreement between the two tests 
(Κ=0.288).19 
Table 3 shows the TB test results of the 
102 pregnant women.  A total of 93 (91.2%) 
had concordant results between both tests 
and nine had discordant results (8.8%). A 
kappa statistic revealed fair agreement 
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Table 1.  Composition of the pregnant and non-pregnant subject groups. 
 Pregnant Subjects 
n=102# 
Non-Pregnant Subjects 
N=50# 
 
p 
Mean Age (sd)* 25.94 (5.25) 29.34 (7.25) 0.004 
Race §    
Caucasian (%) 97 (.97) 37 (.79) <0.001 
African-American (%)  3 (.03)  6 (.13)  
Asian (%)  0 (.00)  4 (.08)  
Ethnicity§    
Hispanic (%) 87 (.87) 12 (.26) <0.001 
Non-Hispanic (%) 13 (.13) 35 (.74)  
#
  Race and ethnicity data were available for 47 of the 50 non-pregnant and 100 of 102 pregnant 
subjects. 
* 
  Two sample t-test with unequal variance. 
§
   Pearson Chi-Square Test. 
 
Table 2.  Comparisons between the QuantiFERON®-TB Gold assay and TST results for all 
subjects. 
  Quantiferon 
  Positive Negative Indeterminate kappa 
 
TST 
Positive 5 (3.3%) 15 (9.9%) 1 (.7%) 0.288 
Negative 2 (1.3%) 126 (82.9%) 3 (2.0%)  
 
 
Table 3.  Comparisons between the QuantiFERON®-TB Gold assay and TST results for pregnant 
subjects. 
  Quantiferon 
  Positive Negative Indeterminate kappa 
TST Positive 3 (3%) 7 (7%) 0 (0%) 0.358 
Negative 2 (2%) 90 (88%) 0 (0%)  
 
 
Table 4.  Comparisons between the QuantiFERON®-TB Gold assay and TST results for all non-
pregnant subjects. 
  Quantiferon 
  Positive Negative Indeterminate kappa 
 
TST 
Positive 2 (4%) 8 (16%) 1 (2%) 0.213 
Negative 0 (0%) 36 (72%) 3 (6%)  
 
 
Table 5.  Level of concordance between the two TB tests in pregnant and non-pregnant subjects. 
 
 
 
 
*
 Fisher’s Exact Test.
 Concordant Discordant p* 
Pregnant 93 (91%) 9 (9%) 0.022 
Non-Pregnant 38 (76%) 12 (24%)  
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between the tests for pregnant women 
(Κ=0.358).   
Table 4 shows the TB test results of the 
50 non-pregnant women.  A total of 38 
(76%) had concordant results between both 
tests and 12 (24%) had discordant results.  A 
kappa statistic also revealed fair agreement 
between the tests for non-pregnant women 
(Κ=0.213).   
Fisher’s exact testing revealed that 
significantly more discordant results 
occurred in non-pregnant than pregnant 
women (X2 = 6.159; p<.022; see Table 5). 
 
Discussion 
The increase in prevalence of 
tuberculosis and the emergence of 
multidrug-resistant strains have created a 
public health urgency for early identification 
of M. tuberculosis-infected individuals.1,2  
The gold standard for detecting exposure 
remains the TST and is one of the oldest 
tests still in clinical use.  Despite the long 
history of clinical application, limitations 
and controversy with regard to placement 
and interpretation remain.2-4 
The TST has several drawbacks 
including   false-positive   reactivity due to 
non-tuberculin strains, such as BCG, inter-
observer variability in reading, false-
negative results due to underlying 
immunosuppression, and variability with 
repeat testing.  Due to changes in disease 
prevalence and demographics, a heightened 
need for early detection and better testing 
methodologies has emerged.2-5 
The Quantiferon test and TST are 
dependant on immune mediators and factors, 
thus, affected by changes in the immune 
system of the tested subjects.  Pregnancy 
certainly falls within that category.  
However, current guidelines favor using 
either test in healthy individuals.9,20 
In this study, results between the two TB 
tests in all subjects (86.2%) showed fair 
agreement between the two tests with 91.2% 
of pregnant women and 76% of non-
pregnant women having concordant results.   
Interestingly, concordance between test 
results in a population of university 
international students was only 59%.21   
Although the groups in this study 
differed by age and race/ethnicity, it is 
doubtful whether these differences were 
clinically significant.  No evidence is 
available that indicates that delayed type 
hypersensitivity reacts differently by 
race/ethnicity or in the relatively narrow age 
range of the reported subjects. 
Even though more discordant results 
occurred in the non-pregnant women, both 
tests were effective in pregnant women.  To 
our knowledge, this is the first study that 
compared both tests in pregnant individuals.  
In conclusion, the TST and Quantiferon tests 
can be used with pregnant women.  The 
decision to use either test in pregnant 
women should be based mainly on the 
compliance of the patient to return to have 
the TST read.  
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